Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds

Weight-loss drugs like Ozempic, developed by Novo Nordisk, have been shown in a new study to potentially reduce rates of opioid and alcohol abuse by up to 50%. The study suggests that these medications may provide additional benefits beyond weight loss and diabetes management, offering hope for addressing substance abuse issues. This research supports the idea that weight-loss drugs could play a significant role in improving overall health outcomes beyond their primary intended use.

Full Article